Crosstalk between Blood Vessels and Tumor Microenvironment

Oral Science International

Volumn 7, Issue 1, 2010, Pages 1-10

  Hida, Kyoko ^a   Ohga, Noritaka ^a   Kurosu, Takuro ^a   Totsuka, Yasunori ^a   Shindoh, Masanobu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

angiogenesis; microenvironment; tumor

Indexed keywords

EID: 84891462039     PISSN: 13488643     EISSN: None     Source Type: Journal    
DOI: 10.11277/osi.osi201004     Document Type: Article

References (49)

1. Kalluri R., and Zeisberg M.: Fibroblasts in cancer. Nat Rev Cancer 6 : 392–401, 2006.
2. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., Graf T., Pollard J.W., Segall J., Condeelis J.: A para-crine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64 : 7022–7029, 2004.
3. Folkman J.: Tumor angiogenesis: therapeutic implications. N Engl J Med 285 : 1182–1186, 1971.
4. Folkman J., and Kerbel R.: Role of angiogenesis in tumor growth and metastasis Clinical translation of angiogenesis inhibitors. Semin Oncol 29 : 15–18, 2002.
5. Folkman J.: Angiogenesis an organizing principle for drug discovery? Nat Rev Drug Discov 6 : 273–286, 2007.
6. Hida K., Hida Y., Amin D.N., Flint A.F., Panigrahy D., Morton C.C., Klagsbrun M.: Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64: 8249–8255, 2004.
7. Hida K., and Klagsbrun M.: A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65 : 2507–2510, 2005.
8. Ohga N., Hida K., Hida Y., Muraki C., Tsuchiya K., Matsuda K., Ohiro Y., Totsuka Y., Shindoh M.: Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells. Cancer Sci, 2009.
9. Hida K., Hida Y., and Shindoh M.: Understanding tumor endothelial cell abnormalities to develop ideal anti-angio-genic therapies. Cancer Sci 99 : 459–466, 2008.
10. Matsuda K., Ohga N., Hida Y., Muraki C., Kurosu T., Tsuchiya K., Akino T., Shih S.C., Totsuka Y., Klagsbrun M., Shindoh M., Hida K.: Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun.
11. Bussolati B., Deambrosis I., Russo S., Deregibus M.C., and Camussi G.: Altered angiogenesis and survival in human tumor-derived endothelial cells. Faseb J 17: 1159–1161, 2003.
12. Akino T., Hida K., Hida Y., Tsuchiya K., Freedman D., Muraki C., Ohga N., Matsuda K., Akiyama K., Harabayashi T., Shinohara N., Nonomura K., Klagsbrun M., Shindoh M.: Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 175 : 2657–2667, 2009.
13. McDonald D.M., and Baluk P.: Significance of blood vessel leakiness in cancer. Cancer Res 62 : 5381–5385, 2002.
14. McDonald D.M., and Choyke P.L.: Imaging of angiogenesis: from microscope to clinic. Nat Med 9 : 713–725, 2003.
15. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M.: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156 : 1363–1380, 2000.
16. Baluk P., Hashizume H., and McDonald D.M.: Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15 : 102–111, 2005.
17. Jain R.K.: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62, 2005.
18. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W.: Genes expressed in human tumor endothelium. Science 289 : 1197–1202, 2000.
19. Carson-Walter E.B., Watkins D.N., Nanda A., Vogelstein B., Kinzler K.W., and St Croix B.: Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61 : 6649–6655, 2001.
20. Nanda A., and St Croix B.: Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 16: 44–49, 2004.
21. Seaman S., Stevens J., Yang M.Y., Logsdon D., Graff-Cherry C., and St Croix B.: Genes that Distinguish Physiological and Pathological Angiogenesis. Cancer Cell 11: 539–554, 2007.
22. Buckanovich R.J., Sasaroli D., O'Brien-Jenkins A., et al.: Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25 : 852–861, 2007.
23. Lu C., Bonome T., Li Y., et al.: Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67: 1757–1768, 2007.
24. van Beijnum J.R., Dings R.P., van der Linden E., et al.: Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108 : 2339–2348, 2006.
25. Amin D.N., Hida K., Bielenberg D.R., and Klagsbrun M.: Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 66: 2173–2180, 2006.
26. Gunsilius E., Duba H.C., Petzer A.L., Kahler C.M., Grunewald K., Stockhammer G., Gabl C., Dirnhofer S., Clausen J., Gastl G.: Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 355 : 1688–1691, 2000.
27. Streubel B., Chott A., Huber D., Exner M., Jager U., Wagner O., Schwarzinger I.: Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351 : 250–259, 2004.
28. Rigolin G.M., Fraulini C., Ciccone M., Mauro E., Bugli A.M., De Angeli C., Negrini M., Cuneo A., Castoldi G.: Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 107 : 2531–2535, 2006.
29. Pezzolo A., Parodi F., Corrias M.V., Cinti R., Gambini C., and Pistoia V.: Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol 25 : 376–383, 2007.
30. Marx J.: Debate surges over the origins of genomic defects in cancer. Science 297 : 544–546, 2002.
31. Weaver B.A., Silk A.D., Montagna C., Verdier-Pinard P., and Cleveland D.W.: Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11 : 25–36, 2007.
32. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., Langer C.J., DeVore R.F., 3rd, Gaudreault J., Damico L.A., Holmgren E., Kabbinavar F.: Randomized phase II trial comparing bev-acizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 : 2184–2191, 2004.
33. Keedy V.L., and Sandler A.B.: Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 98 : 1825–1830, 2007.
34. Kindler H.L., Friberg G., Singh D.A., Locker G., Nattam S., Kozloff M., Taber D.A., Karrison T., Dachman A., Sta-dler W.M., Vokes E.E.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 : 8033–8040, 2005.
35. Saif M.W., Elfiky A., and Salem R.R.: Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14 : 1860–1869, 2007.
36. Kerbel R.S., Yu J., Tran J., Man S., Viloria-Petit A., Kle-ment G., Coomber B.L., Rak J.: Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 20 : 79–86, 2001.
37. Alavi A.S., Acevedo L., Min W., and Cheresh D.A.: Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res 67: 2766–2772, 2007.
38. Vogelstein B., and Kinzler K.W.: Cancer genes and the pathways they control. Nat Med 10 : 789–799, 2004.
39. Kaneko T., Zhang Z., Mantellini M.G., Karl E., Zeitlin B., Verhaegen M., Soengas M.S., Lingen M., Strieter R.M., Nunez G., Nor J.E.: Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res 67 : 9685–9693, 2007.
40. Ferrara N., and Kerbel R.S.: Angiogenesis as a therapeutic target. Nature 438 : 967–974, 2005.
41. Jacobsen B.M., Harrell J.C., Jedlicka P., Borges V.F., Varella-Garcia M., and Horwitz K.B.: Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res 66 : 8274–8279, 2006.
42. Bergsmedh A., Szeles A., Henriksson M., Bratt A., Folk-man M.J., Spetz A.L., Holmgren L.: Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci U S A 98 : 6407–6411, 2001.
43. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., Baran J., Urbanowicz B., Branski P., Ratajczak M.Z., Zembala M.: Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 55 : 808–818, 2006.
44. Deregibus M.C., Cantaluppi V., Calogero R., Lo Iacono M., Tetta C., Biancone L., Bruno S., Bussolati B., Camussi G.: Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 110 : 2440–2448, 2007.
45. Wang X., Willenbring H., Akkari Y., Torimaru Y., Foster M., Al-Dhalimy M., Lagasse E., Finegold M., Olson S., Grompe M.: Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 422 : 897–901, 2003.
46. Duda D.G., Cohen K.S., Kozin S.V., Perentes J.Y., Fuku-mura D., Scadden D.T., Jain R.K.: Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 107 : 2774–2776, 2006.
47. Takakura N.: Role of hematopoietic lineage cells as accessory components in blood vessel formation. Cancer Sci 97 : 568–574, 2006.
48. Bertolini F., Shaked Y., Mancuso P., and Kerbel R.S.: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6 : 835–845, 2006.
49. Nolan D.J., Ciarrocchi A., Mellick A.S., Jaggi J.S., Bambino K., Gupta S., Heikamp E., McDevitt M.R., Schein-berg D.A., Benezra R., Mittal V.: Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 21 : 1546–1558, 2007.